IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1648
COX) Examiner: Lucas, Z.
Serial No.: Not Yet Assigned) <u>INFORMATION DISCLOSURE</u>) STATEMENT
Filed: February 5, 2004)
Atty. File No.: 4152-1-PUS-5) EXPRESS MAIL: EL975241367US
For: "CYSTEINE VARIANTS OF)
GRANULOCYTE COLONY-)
STIMULATING FACTOR")
Commissioner for Patents	
P.O. Box 1450	

Dear Sir:

Alexandria VA 22313-1450

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby submits the enclosed PTO Form 1449. Except for the Hill et al. reference (#16, enclosed), the documents identified herein were of record in U.S. Patent Application Serial No. 10,400,377, and since the above-identified patent application is a continuation thereof, copies of the identified documents are not being submitted under 37 CFR § 1.98(d). Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

y:___*[\filly*

Angela Dallas Sebor Registration No. 42,460

1560 Broadway, Suite 1200 Denver, CO 80202-5141

(303) 863-9700

Date: Fibruary 5, 200 4

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4152-1-PUS-5	SERIAL NO. Not Yet Assigned	
APPLICANT COX		
FILING DATE February 5, 2004	GROUP ART	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP
	1	4,588,585	5/13/86	Mark et al.	424	85	
	2	5,166,322	11/24/92	Shaw et al.	530	351	
	3	5,206,344	4/27/93	Katre et al.	530	351	
	4	5,208,158	5/4/93	Bech et al.	435	219	
	5	5,766,897	6/16/98	Braxton	435	172.1	
	6	5,849,535	12/1998	Cunningham et al.	435	243	

FOREIGN PATENT DOCUMENTS

					SUB CLASS	TRANSLATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	NO
7	0 458 064 A2	11/1991	Europe				
8	WO 93/00109	7/1993	PCT				
9	WO 95/11987	4/1995	PCT	j			
10	WO 96/31537	10/1996	PCT				
 11	WO 95/32003	11/1995	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

12	Bazan, Immunology Today, 11:350-354 (1990)
13	Campbell et al., J. Peptide Res., 49:527-537 (1997)
14	Cunningham et al., Science, 243:1330-1336 (1989)
15	Goodson and Katre, Bio/Technology, 8:343-346 (1990)
16	Hill et al., Proc. Natl. Acad. Sci. USA, 90:5167-5171 (1993)
17	Karpusas et al., <i>Proc. Natl. Acad. Sci. USA</i> , 94 :11813-11818 (1997)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conf not considered. Include copy of this form with next communication to applic	ormance with MPEP 609; Draw line through citation if not in conformance and ant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4152-1-PUS-5	SERIAL NO. Not Yet Assigned	
APPLICANT COX		
FILING DATE February 5, 2004	GROUP ART	

18	Lowman and Wells, <i>J. Mol. Biol.</i> , 234 :564-578 (1993)
19	Mott and Compbell, Curr Opin Struct Biol, 5:114-121 (1995)
20	Sprang and Bazan, Curr. Op. Struct. Biol., 3:815-827 (1993)
21	Wells, Ann. Rev. Biochem., 65:609-634 (1996).
22	Zalipsky, S., <i>Adv. Drug Delivery Rev.</i> , 16 :157-182 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.